Pegfilgrastim

Drug #2245

Pegfilgrastim is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

← Previous drug Next drug →

Primary Characteristics

It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action. It is also classified under Hematological Agents .

Non-proprietary name: Pegfilgrastim.

Pharmacokinetics

None recorded.

Indications

Pegfilgrastim is primarily indicated in conditions like Aplastic anemia, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Myeloablative therapy followed by bone marrow transplantation.

Contraindications

Pegfilgrastim is contraindicated in conditions like Hypersensitivity to the drug.

Dosage

Pegfilgrastim's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
6 mg	6 mg	—	Sc	6 mg administered subcutaneously once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Pegfilgrastim produces potentially life-threatening effects which include Allergic reactions, Respiratory distress syndrome. Careful monitoring is needed with proper medical management.

Pegfilgrastim is known to cause more or less tolerable side effects which are usually transient. These include Arthralgia, Myalgia.

Warnings / Precautions

Fatal splenic rupture can occur. Evaluate for splenomegaly or splenic rupture in patients with left upper abdominal or shoulder pain. Acute respiratory distress syndrome (ARDS) can occur. Evaluate for ARDS in patients who develop fever, lung infiltrates, or respiratory distress. Discontinue in patients with ARDS. Serious allergic reactions, including anaphylaxis, can occur. Permanently discontinue in patients with serious allergic reactions. Severe and sometimes fatal sickle cell crises can occur.

Available Brands

None recorded.

Storage Conditions

Pegfilgrastim should be stored Injection (Keep at 2-8 degree centigrade).

Drug Classification

1.10.4 — Anabolics & hematopoietics